There is a particular tension built into the role of an investor who has also been an operator, as outlined here. Leen Kawas knows both sides of that table with unusual depth. She co-invented the lead drug candidate in Athira Pharma’s pipeline, built the company from the ground up, guided it through multiple late-stage clinical programs, and took it public in 2020, raising more than four hundred million dollars. She has since co-founded Propel Bio Partners, a biotech-focused venture fund, and now sits on the boards of portfolio companies including Inherent Biosciences and Persephone Biosciences. In each of those roles, she has had to answer the same structural question: how much should an investor or board member direct, and how much should they step back and let the founders lead?

Kawas has been consistently clear about where she stands on that question, explored in depth elsewhere. She has described her role at Propel Bio Partners not as conventional oversight but as thoughtful partnership: investing methodically and supporting companies in ways that go considerably beyond writing a check. The distinction matters in practice. An investor who substitutes their judgment for the founder’s creates dependency and erodes the decision-making confidence that early-stage companies need most. An investor who stays entirely at arm’s length provides capital but not the operational intelligence that separates smart money from dumb money. The task is to occupy the space between those two failure modes.

The Mindset She Looks For

Kawas has been explicit that when she evaluates teams for potential investment, the primary variable she assesses is not experience or pedigree. It is mindset. Specifically, she looks for people who approach problems freshly rather than applying the thinking that produced the problem in the first place. She values what she has called a beginner’s mind: the capacity to remain genuinely curious about the problem at hand, to learn from everyone regardless of their seniority level, and to treat each challenge as specific rather than generic.

That criterion shapes how she approaches empowerment. When you have identified founders and teams with the right intellectual orientation, the oversight function changes character. It becomes less about checking whether people are making the right decisions and more about making sure they have the information, the network access, and the strategic perspective to make good decisions themselves. Kawas has described Propel Bio’s model as providing an entire ecosystem of support around the companies it backs, rather than treating funding as the primary value delivered.

What She Learned as a Founder

The experience of building Athira Pharma gave Kawas an unusually direct view of what founders actually need from their investors and board members. She has spoken candidly about the lessons she drew from that period, including the risks of taking on capital too quickly and not paying enough attention to governance structure in the early stages of company formation. Those are the kinds of mistakes that are difficult to see from the inside and that a board member with genuine operational experience can help a founding team avoid without overriding their autonomy.

She has also noted, as reflected on EIT Pharma’s team page, that being genuine and transparent about risk is part of what makes the oversight function credible. A board member who only surfaces in moments of crisis, or who avoids uncomfortable conversations, is not providing oversight in any meaningful sense. Kawas has described honest engagement with the risks and realities of a business as essential, not just to good governance, but to the kind of trust that allows a founder to bring their real problems to a board meeting rather than the polished version of them.

Empowerment as Investment Strategy

There is a financial argument embedded in Kawas’s approach to empowerment that is worth making explicit. She has noted that a majority of the companies Propel Bio Partners has backed feature women in leadership positions. That is not a philanthropic commitment. It reflects a consistent judgment that diverse, empowered leadership teams deliver superior returns. She has pointed to research showing that companies led by women tend to demonstrate higher returns to shareholders, and she has positioned her investment philosophy accordingly: backing diverse leadership because the evidence suggests it outperforms, not despite that evidence.

The logic behind Leen Kawas’s investment philosophy completes a circle. Kawas invests in teams with the right mindset, provides substantive rather than merely financial support, maintains honest rather than performative oversight, and empowers rather than directs the people running the companies. The model reflects a conviction she has carried from her years as a founder (further detail at https://www.inherentbio.com/team/leen-kawas): that the companies most likely to translate breakthrough science into therapies that reach patients are those where the people doing the work are genuinely trusted to do it. Oversight, in that framework, is the condition that makes genuine empowerment safe, not the alternative to it.